Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Chronic Kidney Disease (Japan CKD Study)
jRCT2080223905Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and albuminuria comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Primary composite renal and cardiovascular outcome. Started May 2018; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)albuminuria
Beyond the preview
Go deeper on jRCT2080223905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223905.